- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03622827
Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer (ChESS)
Postoperative Concurrent Chemoradiotherapy Combined With Recombinant Human Endostatin for High-risk Early Stage Cervical Cancer: A Phase II Pilot Study (ChESS).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot phase 2, single arm study to assess the efficacy and safety of concurrent chemoradiotherapy combined with recombinant human endostatin (Endostar) in early stage cervical cancer patients with high risk factor(s).
Postoperative pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total prescription dose of 45-50Gy to PTV region. The external beam radiotherapy should be completed within 6 weeks. Concurrent chemotherapy consists of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks. Recombinant human endostatin (Endostar,15mg/m2/d, civ, d1-7) is applied 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.
Aimed to recruit total of 120 cases in this single arm study. The primary endpoint is 3-year disease-free survival and acute toxicity. Secondary endpoints include time to distant metastasis survival, local-regional recurrence free survival, 3 and 5-year overall survival, and safety and tolerability. Quality of life will be evaluated with EORTC-Q30.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ke Gu, M.D., Ph.D
- Phone Number: 86-13405070898
- Email: dr.guke@hotmail.com
Study Contact Backup
- Name: Zhiliang Ding, M.D.
- Phone Number: 86-18913535515
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215001
- Recruiting
- The Affiliated Suzhou Hospital of Nanjing Medical University
-
Contact:
- Ke Gu, M.D., Ph.D
- Phone Number: 86-13405070898
- Email: dr.guke@hotmail.com
-
Contact:
- Zhiliang Ding, M.D.
- Phone Number: 86-18913535515
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 70 years.
- Histologically confirmed adenocarcinoma or squamous cervical carcinomas.
- Chest CT scan and ultrasound must be done prior to surgery as to rule out distant metastasis.
- Operable patients with clinical diagnosis of FIGO stage IB-IIA cervical cancer.
- Complete radical hysterectomy of cervical cancer is mandatory. All gross diseases must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Para-aortic lymph node sampling is performed according to gynaecologist decision.
- Patients with one of these risk factors:positive pelvic nodes, parametrial invasion, positive surgical margin.OR patients with at least two of following risk factors: tumor size≥4cm,lymphovascular space invasion,stromal invasion≥1/2.
- Performance status 0-2 (ECOG, Eastern Cooperative Oncology Group).
- Adequate organ function is needed, including cardio-respiratory, hepato-renal and hematological reserves: Absolute neutrophil count (ANC)≥1.5×109/L;Platelet count≥100×109/L; ASAT&ALST<1.5 times upper limit of normal (ULN) (With hepatic metastases, ASAT&ALST<5.0 times upper limit of normal);Bilirubin <1.5 times ULN;Creatinine≤1.25×ULN or Creatinine clearance≥50 mL/min.
- Signed written informed consent prior to study entry.
Exclusion Criteria:
- Previous radiation or chemotherapy treatment or major pelvic surgery.
- Patients with distant metastasis confirmed by imaging or pathology.
- Other uncured malignant tumors in the past five years, except the cured skin basal cell carcinoma and breast carcinoma in situ.
- Any prior anticancer therapy.
- Unable to tolerate postoperative concurrent chemoradiotherapy.
- Patients with evidence of being allergic to fluorouracil, cisplatin or Endostar.
- Patients with serious comorbidity that might potentially influence the practice of protocol, including severe infection, myocardial infarction, severe arrhythmia, severe cerebrovascular disease, severe mental disorder, etc.
- Patients with Heart related adverse events or thrombotic events in the past 6 months.
- Patients with hepatitis B, hepatitis C and human immunodeficiency virus (HIV) or any other active viral infections.
- Participate in other clinical researchers.
- The estimated survival<3 months;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemoradiotherapy + Endostar
Chemoradiotherapy with Endostar:
|
Chemoradiotherapy with Endostar:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year Disease-free survival
Time Frame: 3 years
|
From date of surgery until the date of first documented local-regional progression or distant metastasis (determined by CT or MRI scan and/or biopsy) or death (from any cause) assessed up to three years.
|
3 years
|
Acute toxicity
Time Frame: 3 months
|
Evaluate the treatment induced toxicity according to CTCAE 4.0 during the time of chemoradiotherapy and Endostar which starts from the first day of Endostar and lasts three months.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to distant metastasis survival
Time Frame: 3 years
|
Determine the non-distant metastasis survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first distant metastasis event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
Local-regional recurrence free survival
Time Frame: 3 years
|
Determine the local-regional recurrence free survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first local-regional recurrence event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
3-year overall survival rate
Time Frame: 3 years
|
Determine the 3-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 3 years after operation.
|
3 years
|
5-year overall survival rate
Time Frame: 5 years
|
Determine the 5-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 5 years after operation.
|
5 years
|
Quality of Life (QoL)
Time Frame: 3 years
|
Collect QoL data on early-stage cervical cancer patients with high risk factors.
The data is measured by EORTC QLQ-C30 (Version 3.0) according to investigator collection at the starting and ending time of the adjuvant treatment.
EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
The core and disease-specific for cervix modules are selected to estimate treatment related influence on patients' life.
The final score of the questionnaire is collected and analyzed according to detailed scoring procedures from manuals.
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ke Gu, M.D., Ph.D, The Affiliated Suzhou Hospital of Nanjing Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Uterine Cervical Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostar protein
Other Study ID Numbers
- K2018009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Cervical Neoplasms
-
Huazhong University of Science and TechnologyChongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyQilu Hospital of Shandong University; Third Military Medical University; Women... and other collaboratorsRecruitingCervical Cancer | Uterine Cervical Cancer | Uterine Cervical NeoplasmChina
-
Huazhong University of Science and TechnologyZhejiang University; Wuhan Central HospitalUnknownCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
University of AarhusRecruitingUterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine NeoplasmDenmark
-
Siriwan Tangjitgamol, MDPrince of Songkla University; National Research Council of Thailand; Chiang Mai... and other collaboratorsUnknownUterine Cervical CancerThailand
-
Tampere UniversityGlaxoSmithKline; FinnMedi OyEnrolling by invitation
-
University Hospitals Cleveland Medical CenterCompletedUterine Cervical Dysplasia | Uterine Cervical Cancer | Uterine Cervical Neoplasia | Uterine Cervical Intraepithelial Neoplasia
-
Huazhong University of Science and TechnologyShandong University; Zhejiang UniversityCompletedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerChina
Clinical Trials on Chemoradiotherapy+ Endostar
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityUnknownPatients With Esophageal Cancer(Ⅱ-Ⅲ)China
-
Affiliated Hospital of North Sichuan Medical CollegeJiangsu Simcere Pharmaceutical Co., Ltd.Unknown
-
Mansoura UniversityCompletedRectal Cancer | Bowel; Functional SyndromeEgypt
-
Cancer Institute and Hospital, Chinese Academy...Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; West China... and other collaboratorsUnknownLung Neoplasms | Carcinoma, Small CellChina
-
Albert Einstein College of MedicineActive, not recruitingNon-small Cell Lung CancerUnited States
-
Kyungpook National University HospitalRecruiting
-
Beijing Chao Yang HospitalRecruitingLocal Recurrence of Malignant Tumor of Rectum | Circumferential Resection Margin | Intraoperative Perforation of Rectum | Disease-free Survival | Overal SurvivalChina
-
Guizhou Provincial People's HospitalRecruiting
-
China Medical University HospitalUnknownChemoradiation | Rectal CancerTaiwan
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedNon Small Cell Lung CancerChina